West Pharmaceutical Services (WST) Depreciation & Amortization (CF) (2009 - 2026)

West Pharmaceutical Services' Depreciation & Amortization (CF) history runs 18 years deep, the most recent figure standing at $44.6 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 14.07% year-over-year to $44.6 million; the TTM figure through Mar 2026 stood at $174.1 million (up 11.46% YoY), while the FY2025 annual figure was $168.6 million, up 11.07% from the prior year.
• Depreciation & Amortization (CF) came in at $44.6 million for Q1 2026 at West Pharmaceutical Services, down from $46.4 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $46.4 million in Q4 2025 to a low of $28.7 million in Q1 2022.
• A 5-year average of $36.2 million and a median of $34.8 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) slipped 6.81% in 2022 and advanced 20.42% in 2023, its largest moves.
• West Pharmaceutical Services' Depreciation & Amortization (CF) stood at $30.1 million in 2022, then grew by 14.95% to $34.6 million in 2023, then gained by 15.03% to $39.8 million in 2024, then climbed by 16.58% to $46.4 million in 2025, then fell by 3.88% to $44.6 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $44.6 million, $46.4 million, and $42.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison